2026 Q2 Portfolio Activity
In 2026 Q2, Vivo Capital, LLC maintained a portfolio of 53 distinct positions. The most significant new addition was Achieve Life Sciences Inc., now representing 1.64% of the total fund value. They heavily accumulated shares in Arrivent BioPharma Inc, increasing the position by 89.9%. The fund also reduced its exposure to Erasca Inc by 66.0%.
Position History
hover any row below to update
Loading…
Total Positions
53
Quarter
2026 Q2
Top Holding
TRVI (8.7%)
Top 10 Concentration
52.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 53
Vivo Capital, LLC Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
TRVI
Trevi Therapeut...
|
Healthcare | 8.68% | 5.07% |
#1
3
Prev: #4
|
6.5 |
—
|
no change | no change |
P
S
|
5,094,668 | $95,015,558 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PRAX
Praxis Precisio...
|
Healthcare | 8.29% | 9.11% |
#2
Prev: #2
|
4.8 |
—
|
-67,779 | -20.0% |
P
S
|
271,116 | $90,766,926 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ERAS
Erasca Inc
|
Healthcare | 6.90% | 16.41% |
#3
2
Prev: #1
|
3.8 |
—
|
-8,024,068 | -66.0% |
P
S
|
4,127,412 | $75,614,188 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AVBP
Arrivent BioPha...
|
Healthcare | 5.34% | 1.71% |
#4
16
Prev: #20
|
5.6 |
—
|
796,181 | 89.9% |
P
S
|
1,682,097 | $58,436,050 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABVX
Abivax SA - ADR
|
Healthcare | 5.05% | 2.23% |
#5
9
Prev: #14
|
5.5 |
—
|
175,360 | 73.2% |
P
S
|
414,899 | $55,289,441 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TNGX
Tango Therapeut...
|
Healthcare | 3.94% | 3.76% |
#6
1
Prev: #7
|
1.6 |
—
|
-775,011 | -36.0% |
P
S
|
1,379,769 | $43,131,579 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CRVS
Corvus Pharmace...
|
Healthcare | 3.83% | 3.43% |
#7
2
Prev: #9
|
2.5 |
—
|
no change | no change |
P
S
|
2,805,816 | $41,918,891 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DRUG
Bright Minds Bi...
|
Healthcare | 3.57% | 3.39% |
#8
2
Prev: #10
|
2.4 |
—
|
no change | no change |
P
S
|
557,172 | $39,113,474 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SVA
Sinovac Biotech...
|
Unknown | 3.49% | 3.19% |
#9
2
Prev: #11
|
2.4 |
—
|
no change | no change |
P
S
|
5,903,000 | $38,192,410 | 2018 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TENX
Tenax Therapeut...
|
Healthcare | 3.32% | 0.28% |
#10
29
Prev: #39
|
4.3 |
—
|
2,291,667 | 1100.0% |
P
S
|
2,500,000 | $36,375,000 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ACRS
Aclaris Therape...
|
Healthcare | 3.23% | 2.09% |
#11
5
Prev: #16
|
1.8 |
—
|
27,971 | 0.4% |
P
S
|
6,694,637 | $35,414,630 | 2016 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DYN
Dyne Therapeuti...
|
Healthcare | 3.16% | 2.36% |
#12
1
Prev: #13
|
2.3 |
—
|
no change | no change |
P
S
|
1,557,466 | $34,591,320 | 2020 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DNTH
Dianthus Therap...
|
Healthcare | 3.15% | 2.48% |
#13
1
Prev: #12
|
2.3 |
—
|
no change | no change |
P
S
|
353,998 | $34,507,725 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANRO
Alto Neuroscien...
|
Healthcare | 2.91% | 1.94% |
#14
4
Prev: #18
|
3.2 |
—
|
173,307 | 16.7% |
P
S
|
1,208,858 | $31,901,763 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DBVT
DBV Technologie...
|
Healthcare | 2.76% | 4.65% |
#15
10
Prev: #5
|
1.1 |
—
|
-822,811 | -30.8% |
P
S
|
1,844,758 | $30,254,031 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SABS
SAB Biotherapeu...
|
Healthcare | 2.60% | 3.65% |
#16
8
Prev: #8
|
1.0 |
—
|
-4,120,091 | -36.1% |
P
S
|
7,299,909 | $28,469,645 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MLTX
Moonlake Immuno...
|
Healthcare | 2.49% | 1.56% |
#17
7
Prev: #24
|
3.5 |
—
|
400,000 | 40.0% |
P
S
|
1,400,000 | $27,258,000 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LBRX
LB Pharmaceutic...
|
Healthcare | 2.37% | 1.65% |
#18
3
Prev: #21
|
1.9 |
—
|
no change | no change |
P
S
|
800,000 | $25,964,000 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NERV
Minerva Neurosc...
|
Healthcare | 2.19% | 2.17% |
#19
4
Prev: #15
|
1.9 |
—
|
no change | no change |
P
S
|
4,322,747 | $23,991,246 | 2016 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DSGN
Design Therapeu...
|
Healthcare | 2.13% | 1.43% |
#20
5
Prev: #25
|
1.9 |
—
|
no change | no change |
P
S
|
1,612,903 | $23,338,706 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ORIC
Oric Pharmaceut...
|
Healthcare | 1.83% | 1.95% |
#21
4
Prev: #17
|
1.7 |
—
|
no change | no change |
P
S
|
1,848,786 | $20,022,352 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CAMP
CAMP4 Therapeut...
|
Healthcare | 1.69% | 1.56% |
#22
1
Prev: #23
|
1.7 |
—
|
no change | no change |
P
S
|
4,246,568 | $18,557,502 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNSE
Faeth Therapeut...
|
Healthcare | 1.65% | 1.90% |
#23
4
Prev: #19
|
1.7 |
—
|
no change | no change |
P
S
|
722,020 | $18,050,500 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ACHV
Achieve Life Sc...
|
Healthcare | 1.64% | — |
#24
Prev: #—
|
4.2 |
—
|
2,751,032 | — |
NEW
|
2,751,032 | $17,964,239 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CMPX
Compass Therape...
|
Healthcare | 1.55% | 4.21% |
#25
19
Prev: #6
|
1.1 |
—
|
-1,788,406 | -18.7% |
P
S
|
7,757,060 | $16,987,961 | 2021 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANTX
AN2 Therapeutic...
|
Healthcare | 1.39% | 0.90% |
#26
3
Prev: #29
|
1.6 |
—
|
no change | no change |
P
S
|
3,153,640 | $15,263,618 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EDIT
Editas Medicine...
|
Healthcare | 1.05% | — |
#27
Prev: #—
|
3.9 |
—
|
3,555,250 | — |
NEW
|
3,555,250 | $11,519,010 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GERN
Geron Corp
|
Healthcare | 1.01% | 1.08% |
#28
1
Prev: #27
|
1.4 |
—
|
no change | no change |
P
S
|
8,671,797 | $11,099,900 | 2022 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
Odyssey Therape...
|
|
Unknown | 0.98% | — |
#29
Prev: #—
|
3.9 |
—
|
575,000 | — |
NEW
|
575,000 | $10,758,250 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
EPRX
Eupraxia Pharma...
|
Healthcare | 0.81% | 0.82% |
#30
2
Prev: #32
|
1.3 |
—
|
no change | no change |
P
S
|
1,350,000 | $8,923,500 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OKUR
Onkure Therapeu...
|
Healthcare | 0.80% | 0.67% |
#31
2
Prev: #33
|
1.3 |
—
|
no change | no change |
P
S
|
1,927,710 | $8,790,358 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OLMA
Olema Pharmaceu...
|
Healthcare | 0.77% | 0.84% |
#32
2
Prev: #30
|
1.3 |
—
|
no change | no change |
P
S
|
671,843 | $8,404,756 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MNPR
Monopar Therape...
|
Healthcare | 0.77% | 0.41% |
#33
3
Prev: #36
|
1.3 |
—
|
no change | no change |
P
S
|
90,500 | $8,379,395 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AURA
Aura Bioscience...
|
Healthcare | 0.76% | — |
#34
Prev: #—
|
3.8 |
—
|
1,166,667 | — |
NEW
|
1,166,667 | $8,283,336 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SRZN
Surrozen Inc
|
Healthcare | 0.62% | 0.63% |
#35
1
Prev: #34
|
1.2 |
—
|
no change | no change |
P
S
|
260,000 | $6,747,000 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALXO
ALX Oncology Ho...
|
Healthcare | 0.60% | 0.53% |
#36
1
Prev: #35
|
1.2 |
—
|
no change | no change |
P
S
|
3,184,713 | $6,592,356 | 2020 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
Satellos Biosci...
|
|
Unknown | 0.58% | — |
#37
Prev: #—
|
3.7 |
—
|
813,666 | — |
NEW
|
813,666 | $6,326,253 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
AVTX
Avalo Therapeut...
|
Healthcare | 0.46% | — |
#38
Prev: #—
|
3.7 |
—
|
275,000 | — |
NEW
|
275,000 | $5,082,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PEPG
Pepgen Inc
|
Healthcare | 0.38% | 0.34% |
#39
2
Prev: #37
|
1.2 |
—
|
no change | no change |
P
S
|
2,325,000 | $4,185,000 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VALN
Valneva SE
|
Healthcare | 0.36% | — |
#40
Prev: #—
|
3.6 |
—
|
763,199 | — |
NEW
|
763,199 | $3,991,531 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SERA
Sera Prognostic...
|
Healthcare | 0.27% | 0.28% |
#41
3
Prev: #38
|
1.1 |
—
|
no change | no change |
P
S
|
1,650,440 | $3,003,801 | 2021 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
UNCY
Unicycive Thera...
|
Healthcare | 0.24% | 0.98% |
#42
14
Prev: #28
|
0.1 |
—
|
-1,239,916 | -69.3% |
P
S
|
550,000 | $2,579,500 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TIL
Instil Bio Inc
|
Healthcare | 0.21% | 0.20% |
#43
2
Prev: #41
|
1.1 |
—
|
no change | no change |
P
S
|
292,743 | $2,251,194 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
INM
InMed Pharmaceu...
|
Healthcare | 0.11% | — |
#44
Prev: #—
|
3.5 |
—
|
798,377 | — |
NEW
|
798,377 | $1,237,484 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BOLT
Bolt Biotherape...
|
Healthcare | 0.03% | 0.02% |
#45
1
Prev: #44
|
1.0 |
—
|
no change | no change |
P
S
|
72,414 | $278,794 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KTTA
Pasithea Therap...
|
Healthcare | 0.02% | 0.13% |
#46
4
Prev: #42
|
0.0 |
—
|
-1,634,529 | -77.8% |
P
S
|
465,471 | $239,904 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DTIL
Precision Biosc...
|
Healthcare | 0.00% | 0.00% |
#47
2
Prev: #45
|
1.0 |
—
|
no change | no change |
P
S
|
4,675 | $36,746 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CMPS
Compass Pathway...
|
Healthcare | 0.00% | 0.09% |
Sold All 😨
(Was: #43) |
0.0 |
—
|
-200,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VRDN
Viridian Therap...
|
Healthcare | 0.00% | 0.27% |
Sold All 😨
(Was: #40) |
0.0 |
—
|
-166,288 | -100.0% |
CLOSED
|
— | $— | 2021 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SLNO
Soleno Therapeu...
|
Healthcare | 0.00% | 0.82% |
Sold All 😨
(Was: #31) |
0.0 |
—
|
-294,909 | -100.0% |
CLOSED
|
— | $— | 2017 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-50 of 53 holdings